Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sun Pharma Merges Taro Pharma with Subsidiary | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sun Pharma Merges Taro Pharma with Subsidiary

Taro is now a private company and wholly-owned by Sun Pharma.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Sun Pharmaceutical Industries Limited has completed the merger of Taro Pharmaceutical Industries Ltd. with its subsidiary. 
 
As part of this merger, Sun Pharma acquired all outstanding ordinary shares of Taro other than those already held by Sun Pharma or its affiliates. As a result of the merger, Taro is now a private company and wholly owned by Sun Pharma. Sun Pharma has been the majority shareholder of Taro since 2010.
 
Dilip Shanghvi, Chairman and Managing Director of Sun Pharma, said, “We are pleased with the successful completion of Taro merger process. This milestone marks a significant step forward for both organizations, allowing us to effectively leverage each other’s strengths and capabilities. Together, we are excited about starting this new chapter and creating a more robust, successful future for the combined entity.”

More Sun Pharma News

Last year, Sun Pharma acquired Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company.

Also, don’t miss Contract Pharma’s 2024 Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics